Oxybuprocaine

S01H - Local anesthetics ATC S01HA02 Small molecule approved 1982 Topical Natural product

JFDA label: Minims Oxybuprocaine Hcl 0.4% e/d

Mechanism of Action

Prevents initiation and transmission of impulse at the nerve cell membrane by decreasing ion permeability through stabilizing

Indications

Approved

Anesthesia, ocular

Contraindications

Source: Lexicomp

Hypersensitivity to proparacaine or any component of the formulation Absolute

Adverse Reactions

Very Common >10%Common 1–10%Uncommon 0.1–1% Rare 0.01–0.1%Very Rare <0.01%Not Known

Immune system disorders (1)

Not Known Hypersensitivity reaction (corneal; characterized by acute, intense, and diffuse epithelial keratitis; gray, ground glass appearance; exfoliation of skin; corneal filaments; and can include iritis wit

Skin and subcutaneous tissue disorders (1)

Not Known Allergic contact dermatitis

Eye disorders (8)

Not Known Burning sensation of eyes · conjunctival hemorrhage · conjunctival hyperemia · corneal erosion · cycloplegia · eye redness · mydriasis · stinging of eyes

Dosing

Source: Lexicomp

Anesthesia, ocular: Short corneal and conjunctival procedures: Ophthalmic: Instill 1 drop in eye(s) every 5 to 10 minutes for 5 to 7 doses Tonometry, gonioscopy, suture removal: Ophthalmic: Instill 1 to 2 drops in eye(s) just prior to procedure

(For additional information see "Proparacaine: Pediatric drug information") Children and Adolescents: Refer to adult dosing

Refer to adult dosing.

No dosage adjustment provided in manufacturer’s labeling.

There are no dosage adjustments provided in the manufacturer’s labeling.

Warnings & Precautions

Source: Lexicomp

Appropriate use

For topical ophthalmic use only; prolonged use may result in permanent corneal opacification and visual loss and is not recommended.

Pregnancy & Lactation

Pregnancy

FDA category C

Animal reproduction studies have not been conducted.

Lactation

It is not known if proparacaine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering proparacaine to nursing women.

Chemistry & Properties

Formula	C17H28N2O3
Molecular weight	308.42 g/mol
IUPAC name	2-(diethylamino)ethyl 4-amino-3-butoxybenzoate
CAS	99-43-4
PubChem CID	4633
InChIKey	`CMHHMUWAYWTMGS-UHFFFAOYSA-N`
logP	2.95 (XLogP 3.1)
Polar surface area	64.79 Å²
H-bond acceptors / donors	5 / 1
Drug-likeness (QED)	0.41
Lipinski violations	0

SMILES

CCCCOc1cc(C(=O)OCCN(CC)CC)ccc1N

Biology & Pharmacokinetics

Pharmacokinetics

BBB penetrant	No

Enzyme interactions

Enzyme	Role	Detail
CYP1A2	Inhibitor	—
CYP2B6	Inhibitor	—
CYP2D6	Inhibitor	—

Transporters

BCRP (Inhibitor)BSEP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)

Registered Products (1)

Brand	Form / strength	Pack	Agent	Citizen (JOD)
Minims Oxybuprocaine Hcl 0.4% e/d	Ophthalmic Solution 0.4 %	0.5 ml	Petra Drug Store	—